EGFRvⅢ and immunotherapy of glioblastoma multiforme
10.3872/j.issn.1007-385x.2018.05.001
- VernacularTitle:EGFRvⅢ与成胶质细胞瘤的免疫治疗
- Author:
WU Junchao
1
,
2
;
LU Di
1
,
2
;
HAN Shuangyin
1
,
2
Author Information
1. Key Laboratory of Kidney Disease Immunization in Henan Province, People'
2. s Hospital of Zhengzhou University, Zhengzhou 450003, Henan, Chin
- Publication Type:Journal Article
- Keywords:
epidermal growth factor receptor variant Ⅲ (EGFRvIII);
glioblastoma multiforme;
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2018;25(5):441-446
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] EGFRvIII (epidermal growth factor receptor variant Ⅲ) is the most common mutant of epidermal growth factor receptor, which expresses in over 30% glioblastoma multiforme (GBM). EGFRvIII results from deletion of exon 2-7, leading to its constitutive activation, which is closely related to tumorigenesis, development and poor prognosis of GBM. The unique glycine site on EGFRvIII provides ideal molecular target for immunotherapy, which possess great potential value of killing GBM cell, inhibiting progress and invasion. Encouraging progress has been achieved in peptide/DC vaccine, therapeutic antibody, small molecular inhibitor and adoptive immunotherapy experimentally and clinically. The characteristics of EGFRvIII and the development in its oriented immunotherapy were summarized in this review.
- Full text:20180501.pdf
